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Background
Epidemiological studies show a strong correlation
between vitamin D deficiency and asthma severity.
Genetic studies have identified vitamin D receptor poly-
morphisms as a risk factor for asthma in diverse human
populations. Calcitriol (1,25-dihydroxyvitamin D3), the
physiologically active metabolite of mammalian vitamin
D, is able to modulate receptor and cytokine expression
as well as cell differentiation and maturation of various
leukocytes in an anti-inflammatory manner. Despite the
role of eosinophils in allergic asthma pathology, little
is known about the effects of calcitriol on eosinophil
biology. Calcitriol has a direct modulatory effect on
eosinophil survival and effector functions in vitro.
Methods
Human peripheral blood eosinophils from atopic donors
were isolated and incubated with calcitriol (VD) and
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interleukin-5 (IL-5). Dose-response assays tested physiolo-
gical doses of calcitriol (0.01-100 nM). The potentiating
effect of calcitriol (10 nM) on eosinophil survival with IL-5
(1 ng/mL) was investigated on a 14-day time course.
Viability/apoptosis/necrosis levels were obtained using an
Annexin-V/PI flow cytometry assay. Eosinophil crystalloid
granules and EPX release were measured by CD63 and
EPX monoclonal antibody staining using flow cytometry.
EPX activity was determined using an OPD substrate
colorimetric assay.
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Results
Eosinophil survival increased after 24 h of calcitriol
treatment in a dose-dependent manner (Fig1. n = 5).
Calcitriol alone yielded similar eosinophil survival rates
(Fig2.4.5 ± 1.5%, n = 11) after 7 days compared to
control media (Fig2. 2.1 ± 2.1%, n = 11). In contrast,
calcitriol potentiated the survival effect of IL-5 starting
from day 7. At 14 days, 66 ± 7% of eosinophils were still
intact when treated with calcitriol and IL-5, compared
to IL-5 alone (Fig2. 34 ± 8%, p < 0.05, n = 4). Cells
treated with IL-5 alone showed increased necrosis from
day 7 onward with 32% additional necrotic eosinophils
at day 14, compared to the combined treatment. As
cell debris increased in correlation with necrosis
(Fig3 A&B.), low-SSC/FSC events stained positive for
CD63 and EPX confirming whole, intact crystalloid
granules along with free EPX in media (Fig4.). More-
over, EPX activity in media was reduced on days 4 and 7
following calcitriol and IL-5 treatment (Fig5.). Overall,
reduced spontaneous EPX release strongly correlated
with increased eosinophil survival (Fig6. r2 = 0.96,
n = 4-11).
Conclusions
These findings support the hypothesis that calcitriol
plays an anti-inflammatory role by decreasing cytotoxic
granule release into airway mucosal tissues during
allergic inflammatory responses, therefore reducing
mucosal inflammation and tissue damage.
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